Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women

Osteoporosis International

Volumn 14, Issue 10, 2003, Pages 814-822

  Weinstein, Robert S ^a   Parfitt, A Michael ^a   Marcus, Robert ^b,d   Greenwald, Maria ^c   Crans, Gerald ^d   Muchmore, Douglas B ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c Osteoporosis Medical Center   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Activation frequency; Bone formation; Bone histomorphometry; Cancellous bone; Endocortical bone; SERM

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; CONJUGATED ESTROGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PLACEBO; RALOXIFENE; TETRACYCLINE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE CELL; BONE DENSITY; BONE MARROW; BONE MASS; BONE MINERAL; BONE TURNOVER; CANCELLOUS BONE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINE;

AGED; BIOPSY; BONE AND BONES; BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MENOPAUSE; MIDDLE AGED; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0344445501     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-003-1434-z     Document Type: Article

References (25)

1. Grady D, Hulley SB (2000) Editorial: hormones to prevent coronary heart disease in women; when are observational studies adequate evidence? Ann Intern Med 133:999-1001
2. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288(3):321-333
3. Grant C, Gray A, Paoletti R et al (1999) Clinical synthesis conference: hormone replacement therapy. Lancet 354:152-155
4. Mitlak BH, Cohen FJ (1999) Selective estrogen receptor modulators: a look ahead. Drugs 57:653-663
5. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1641-1647
6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE). JAMA 282:637-645
7. Prestwood KM, Gunness M, Wong M, Lu Y, Muchmore D, Raisz L (2000) A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 85:2197-2202
8. Keshawarz NM, Recker RR (1984) Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Rel Res 5:223-228
9. Brown JB, Delmas PD, Arlot M, Meunier PJ (1987) Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab 64:654-659
10. Weinstein RS, Bell NH (1988) Diminished rates of bone formation in normal black adults. N Engl J Med 319:1698-1701
11. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
12. Arlot ME, Delmas PD, Chappard D, Meunier PJ (1990) Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women. Osteoporos Int 1:41-49
13. Riggs BL, Khosla S, Melton LJ (1998) A unitary model for involutional osteoporosis; estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 12:763-773
14. Weinstein RS, Manolagas SC (2000) Apoptosis and osteoporosis. Am J Med 108:153-164
15. Parfitt AM (1992) The two-stage concept of bone loss revisited. Triangle 31:99-110
16. Balena R, Shih M-S, Parfitt AM (1992) Bone resorption and formation on the periosteal envelope of the ilium; a histomorphometric study in healthy women. J Bone Miner Res 7:1475-1482
17. Shih M-S, Cook MA, Spence CA, Palnitkar S, McElroy H, Parfitt AM (1993) Relationship between bone formation rate and osteoblast surface on different subdivisions of the endosteal envelope in aging and osteoporosis. Bone 14:519-521
18. Han Z-H, Palnitkar S, Rao DS, Nelson D, Parfitt AM (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12:498-508
19. Reid I, Fogelman I, Eastell R, Sarkar S, Wu W, Ciaccia A, Draper M (2000) Impact of hysterectomy in studies of raloxifene in healthy and osteoporotic postmenopausal women [abstract]. In: 11th international congress of endocrinology abstract book, Sydney, Australia, 29 October-2 November, 2000 (Abstract P340)
20. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates J, Lombardi A (1999) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 85:720-726
21. Vedi S, Compston JE (1996) The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. Bone 19:535-539
22. Johnson CC, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H, Gennari C, Christiansen C, Arnaud CD, Delmas PD (2000) Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 160:3444-3450
23. Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW (1999) Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 10:330-336
24. Agnusdei D, Iori N (2000) Raloxifene: results from the MORE study. J Musculoskel Neuron Interact 1:127-132
25. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerboeker RK, Riggs BL (1998) Treatment of established postmenopausal with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754